Analysis method for impurity detection of telmisartan tablet and telmisartan capsule

A technique for analyzing telmisartan and its analysis method is applied in the analysis field of impurity detection of telmisartan tablets and telmisartan capsules. Effects of reduced analysis cost, reduced solvent usage, and shortened analysis time

Active Publication Date: 2020-02-25
江西杏林白马药业股份有限公司
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0063] Due to the large number of impurities related to telmisartan and their relatively similar structures, it brings great difficulties to the subsequent analysis and detection of impurities
Compared with the impurity detection technology of the quality standards of telmisartan in the existing pharmacopoeias of various countries, the European Pharmacopoeia, the British Pharmacopoeia, the United States Pharmacopoeia and the Japanese Pharmacopoeia are all determined by high performance liquid chromatography, and all adopt the gradient elution method, but none of the above The 8 kinds of telmisartan impurities were completely separated, and the baseline was poor, which affected the detection of impurities; moreover, sodium n-pentanesulfonate was added to the mobile phase of these impurity detection technologies, which belonged to ion-pair reagents, and ion-pair reagents would Cause irreversible damage to the chromatographic column, the combination of ion-pairing reagent and stationary phase will produce irreversible adsorption, and then affect the active site of the stationary phase; such as octadecyl silica gel bonded column, ion-pairing reagent will affect the bonding of the column, so as to Analysis of the role of the sample, this reaction has a great impact on the chromatographic column, and the ion-pairing reagent is difficult to wash from the chromatographic column, which will greatly shorten the service life of the chromatographic column; the concentration of the ion-pairing reagent has a direct relationship with the retention time of the sample In addition, ion-pair reagents are more sensitive to the pH value, and high precision is required when preparing the mobile phase, otherwise it will directly affect the repeatability and reproducibility of the experiment
Although no ion-pairing reagent is added to the mobile phase of Telmisartan in Chinese Pharmacopoeia, this chromatographic condition is only used to detect impurity I, and cannot completely detect and separate the above 8 kinds of Telmisartan impurities

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Analysis method for impurity detection of telmisartan tablet and telmisartan capsule
  • Analysis method for impurity detection of telmisartan tablet and telmisartan capsule
  • Analysis method for impurity detection of telmisartan tablet and telmisartan capsule

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0095] In order to further shorten the retention time of the main peak of telmisartan, increase the resolution between impurities, and reduce baseline fluctuations, the chromatographic conditions in Comparative Example 5 were optimized again, as shown below.

[0096] Instrument: Waters ACQUITY ARC (UHPLC)

[0097] Chromatographic column: C18, 250mm×4.6mm 3μm

[0098] Solution Ⅰ: Dissolve 2.0 g of potassium dihydrogen phosphate in an appropriate amount of water, adjust the pH to 3.0 with phosphoric acid, and add water to make 1 L;

[0099] Solution Ⅱ: Acetonitrile-Methanol (4:1)

[0100] Mobile phase A: solution Ⅰ-solution Ⅱ (80:20), ultrasonic degassing, that is;

[0101] Mobile phase B: solution Ⅰ-solution Ⅱ (20:80), ultrasonic degassing, that is;

[0102] Flow rate: 1mL / min Detection wavelength: 230nm

[0103] Column temperature: 40°C Injection volume: 20μl

[0104] The gradient elution program is shown in Table 3:

[0105] Table 3 Gradient elution program

[0106] ...

Embodiment 2

[0115] After methodological verification of the telmisartan impurity analysis method in the present invention, it was confirmed that the system applicability, specificity, quantitative limit and inspection limit, linearity and range, accuracy, repeatability and durability of the method all met the verification requirements; Then, the ultra-high performance liquid chromatography of the present invention is used to detect the related substances of the reference preparation and the self-developed telmisartan capsule.

[0116] Chromatographic conditions: with embodiment 1

[0117] Diluent: same as embodiment 1

[0118] Impurity contrast stock solution: with embodiment 1

[0119] System suitability solution: same as embodiment 1

[0120] Reference preparation solution: take an appropriate amount of telmisartan tablets-mecasu (644835, 644263, 644434), grind it finely, accurately weigh an appropriate amount of fine powder (approximately equivalent to telmisartan 50mg), put it in a ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
Login to view more

Abstract

The invention provides an analysis method for the impurity detection of a telmisartan tablet and a telmisartan capsule and belongs to the field of drug detection. The method provided by the inventioncan be adopted to carrying out qualitative and quantitative analysis on impurities in the telmisartan tablet and the telmisartan capsule by using an ultra-high-performance liquid chromatography method, and the impurities comprise any one or more of an impurity A, an impurity B, an impurity C, an impurity E, an impurity F, an impurity G, an impurity H and an impurity I. Compared with a traditionalhigh-performance liquid chromatography method, the ultra-high-performance liquid chromatography method adopted by the invention has the advantages that the analysis time is shortened, at the same time, the solvent consumption is reduced, and the analysis cost is reduced; an ion pair reagent is not added into a mobile phase, and the service life of a chromatographic column is greatly prolonged. According to the method, telmisartan and the eight telmisartan impurities can be completely separated, the base line is good, the quantification limit is high, and the qualitative and quantitative determination of the telmisartan capsule impurities is better facilitated.

Description

technical field [0001] The invention relates to the field of drug detection, in particular to an analysis method for detecting impurities in telmisartan tablets and telmisartan capsules. Background technique [0002] The chemical name of Telmisartan is 4'-[[4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]-2 -Bibenzoic acid, the molecular formula is C 33 h 30 N 4 o 2 . This product is a specific non-peptide angiotensin II receptor antagonist, which can selectively block the binding of angiotensin II in vascular smooth muscle and adrenal gland to its receptor subtype AT1, thereby blocking vasoconstriction and aldosterone secretion. Secreted, produce antihypertensive effect. This product can reduce both systolic and diastolic blood pressure without affecting heart rate, has no partial agonist effect at the AT1 receptor site, does not inhibit the activity of angiotensin converting enzyme, and does not bind to or produce other receptors or ion channe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/88
CPCG01N30/88G01N2030/8809
Inventor 李保林刘一平罗云华朱勤
Owner 江西杏林白马药业股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products